Merck KGaA offloads failed MEK programme to startup Day OneUS biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s Share XMerck KGaA offloads failed MEK programme to startup Day Onehttps://pharmaphorum.com/news/merck-kgaa-offloads-failed-mek-programme-to-startup-day-one/
COVID-19 increased demands on carers’ wellbeing, study findsCOVID-19 has increased demands on informal carers and severely increased demands on their mental, physical and financial wellbeing, Share XCOVID-19 increased demands on carers’ wellbeing, study findshttps://pharmaphorum.com/news/covid-19-increased-demands-on-informal-carers-wellbeing-study-finds/
Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenancePfizer and partner Merck KGaA now have approval on both sides of the Atlantic for their checkpoint inhibitor Share XMerck, Pfizer get EU nod for Bavencio as bladder cancer maintenancehttps://pharmaphorum.com/news/merck-pfizer-get-eu-nod-for-bavencio-as-bladder-cancer-maintenance/
GSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialGlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after Share XGSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trialhttps://pharmaphorum.com/news/gsk-merck-cos-hopeful-bintrafusp-alfa-fails-in-key-lung-cancer-trial/
Merck KGaA signs DNA damage response cancer deal with Artios PharmaGermany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel Share XMerck KGaA signs DNA damage response cancer deal with Artios Pharmahttps://pharmaphorum.com/news/merck-kgaa-signs-dna-damage-response-cancer-deal-with-artios-pharma/
Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancerThe Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including Share XScotland backs Merck/Pfizer’s Bavencio combo for kidney cancerhttps://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/
FDA starts quick review of Merck’s MET-targeting lung cancer drugMerck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer Share XFDA starts quick review of Merck’s MET-targeting lung cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/
NICE backs kidney cancer combination from Merck KGaA and PfizerNICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first Share XNICE backs kidney cancer combination from Merck KGaA and Pfizerhttps://pharmaphorum.com/news/nice-backs-kidney-cancer-combination-from-merck-kgaa-and-pfizer/
Merck KGaA takes second option from cancer immunotherapy pact with F-StarGermany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics. The companies Share XMerck KGaA takes second option from cancer immunotherapy pact with F-Starhttps://pharmaphorum.com/news/merck-kgaa-takes-second-option-from-cancer-immunotherapy-pact-with-f-star/
